Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Recursion Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 3.24 · gapped above the open, then crossed back over prior close. High/low 3.40 at 7:45 am ET, 3.23 at 10:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In addition, we are obligated to pay Takeda low-to-mid single-digit royalties based on net sales of products containing the licensed compounds by us, our affiliates or sublicensees, subject to specified reductions.”
FILING10-K0001601830-26-000039cik 0001601830
“In July 2025, we entered into a Membership Interest Purchase Agreement (the "ENPP1 Purchase Agreement") with Recursion Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion ("Buyer") and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner Recursion) (the "JV Sale").”
FILING10-K0001628280-26-018261cik 0001739410disclosed by RLYB
“Under the Recursion Agreement, we agreed to provide certain of our services and to license certain data to Recursion, including a limited right to access our proprietary database of de-identified clinical and molecular data for certain therapeutic product development purposes.”
FILING10-K0000950170-25-025603cik 0001717115disclosed by TEM
“Pursuant to the Asset Purchase Agreement, we shall pay Apeiron a single digit royalty, net of any applicable withholding taxes, if we or a third party commercializes REC-617.”
FILING10-K0001601830-26-000039cik 0001601830
“In July 2023, we issued an aggregate of 7.7 million shares of our Class A common stock at a purchase price of $6.49 per share in the 2023 Private Placement with NVIDIA Corporation for net proceeds of approximately $49.9 million.”
FILING10-K0001601830-26-000039cik 0001601830
“In February 2026, we achieved our fifth milestone across the collaboration, generating a $4 million payment from Sanofi.”
FILING10-K0001601830-26-000039cik 0001601830
“Merck KGaA, Darmstadt, Germany made an upfront cash payment of $20 million to us on signing the RCA, and we remain eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones, if all milestones for all three initial programs are achieved.”
FILING10-K0001601830-26-000039cik 0001601830
“In September 2024, we received a Phenomap acceptance fee of $30.0 million from our collaboration with Roche.”
FILING10-K0001601830-26-000039cik 0001601830
“In February 2025, the Company terminated the Sales Agreement with Jefferies LLC and entered into a Sales Agreement with Citigroup Capital Markets Inc., to provide for the offering, issuance and sale of up to an aggregate amount of $500 million of its Class A common stock.”
FILING10-K0001601830-26-000039cik 0001601830
“In October 2024, we announced an expanded collaboration with Google Cloud leveraging their technologies to accelerate drug discovery research and further enhance our ability to bring new medicines to patients faster.”
FILING10-K0001601830-26-000039cik 0001601830
“In July 2023, we entered a strategic collaboration with NVIDIA to accelerate the development of our groundbreaking AI foundation models for biology and chemistry using our supercomputer, BioHive-1, and priority access on NVIDIA DGX™ Cloud.”
FILING10-K0001601830-26-000039cik 0001601830
“In April 2025, we entered into a license agreement with HealthVerity to access de-identified records for over 340M covered lives in the US.”
FILING10-K0001601830-26-000039cik 0001601830
“In May 2024, we entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records including Helix's Exome+® genomic data and data from longitudinal health records.”
FILING10-K0001601830-26-000039cik 0001601830
“In August 2023, Recursion entered into an Open Market Sales Agreement with Jefferies LLC to provide for the offering, issuance and sale of up to an aggregate amount of $300.0 million of its Class A Common stock.”
FILING10-K0001601830-26-000039cik 0001601830
“In exchange for these rights, the Company paid Tempus an initial license fee in an amount equal to $22.0 million, or the Initial License Fee and agreed to pay annual license fees during the Term ranging between $22.0 million and $42.0 million, which, together with the Initial License Fee, totals up to $160.0 million over the Term, subject to the Company's early termination, which may be triggered only following the third anniversary of the Master Agreement's effective date, and payment by the Company of an early termination fee (as further discussed below).”
FILING10-K0001601830-26-000039cik 0001601830
“Under the Restated Agreement, Bayer has the first option to license potential candidates; each such license could potentially result in option exercise fees and development and commercial milestones paid to Recursion with an aggregate value of up to approximately $210.0 million for one license and up to approximately $1.5 billion if each program is licensed, as well as tiered royalties for each such license, ranging from low- to mid-single digit percentages of sales, depending on commercial success.”
FILING10-K0001601830-26-000039cik 0001601830
“In December 2025, we reported on a natural history analysis in collaboration with Amsterdam University Medical Centre to contextualize the single-arm efficacy TUPELO trial of REC-4881, and to better understand the natural history of FAP.”
FILING10-K0001601830-26-000039cik 0001601830
Watchlist prices, news filtered to it, and its next report on your desk.
Recursion Pharmaceuticals, Inc. has 12 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Recursion Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
RXRX (Recursion Pharmaceuticals, Inc.) has 12 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TEM +9.92%, in cloud.